The US Food and Drug Administration (FDA) has approved a new oral formulation of palonosetron hydrochloride (Aloxi) for the prevention of chemotherapy-induced nausea and vomiting (CINV). Oral administration of palonosetron capsules is indicated for the prevention of acute nausea and vomiting following initial and repeat courses of moderately emetogenic chemotherapy. A single 0.5-mg palonosetron capsule is administered approximately 1 hour prior to the start of chemotherapy. More>>

A 22-year-old woman has had chronic nausea, emesis with green vomitus, and diarrhea for the past 10 months. The diarrhea is frequent (about 3 to 8 times daily) and does not resolve with starvation. More>>

A 44-year-old man presents to the emergency department (ED) with light-headedness, nausea, and vomiting of 1 day's duration. He has also had intermittent palpitations but denies chest pain, dyspnea, and weakness. More>>

A review of "Chemotherapy-Induced Nausea and Vomiting: Which Antiemetic for Which Therapy?" More>>

A review of "Chemotherapy-Induced Nausea and Vomiting: Which Antiemetic for Which Therapy?" More>>

Chemotherapy-induced nausea and vomiting (CINV) remains an important and common toxicity of cancer treatment. Recent guideline revisions have classified chemotherapeutic agents into four categories of emesis risk without the use of preventive agents: high (> 90%), moderate (30%-90%), low (10%-30%), and minimal (< 10%). Currently available antiemetic agents, including corticosteroids, 5-hydroxytryptamine (HT)3 receptor antagonists, and neurokinin (NK)-1 antagonists are used alone or in... More>>

A review of "Chemotherapy-Induced Nausea and Vomiting: Which Antiemetic for Which Therapy?" More>>

To reduce the terrible nausea and vomiting associated with chemotherapy, have patients drink club soda with lemon or lime an hour before mealtime. More>>

LAS VEGAS -- An implanted device approved for treating the chronic nausea and vomiting associated with gastroparesis may also be useful for relieving these idiopathic symptoms in patients with normal gastric emptying. More>>

A 68-year-old woman presents with recurrent nausea, vomiting, left upper quadrant pain, decreased appetite, and a 2.3-kg (5-lb) weight loss 1 month after she underwent selective splenic artery embolization for refractory thrombocytopenia secondary to hypersplenism. More>>